SILDAN

In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) 11, 12, 13, 14, 15, 16, 8, 9.

The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid 11, 12, 13, 14, 15, 16, 8, 9.

Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment for angina.

• or chest pain associated with inadequate blood flow to the heart.

• before being serendipitously indicated for treating erectile dysfunction in the late 1980s 7.

Nevertheless, it is because of this mechanism that sildenafil is also indicated for treating pulmonary arterial hypertension but is also additionally notorious for interacting with various anti-anginal or anti-hypertensive agents to develop potentially rapid, excessive, and/or fatal hypotensive crises 4, 5, 6.

Regardless, sildenafil, among a variety of other similar or related PDE5 inhibitors, has become a common and effective treatment for erectile dysfunction and since its formal approval for medical use in the public in 1998 7, continues to see millions of prescriptions written for it internationally.

Although the medication has historically been most popularly recognized as Pfizer's brand name Viagra, sildenafil is currently available generically and even as a non-prescription over the counter medication in some countries 10.

Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications: the treatment of erectile dysfunction 5, 8, 12, 13, 16; and treatment of pulmonary hypertension, where: the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening 11.

The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy 11.

Studies establishing effectiveness were short-term (12-16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) 11; b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy 14.

In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy 14; and c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity 15.

Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease 15.

EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension 15.

Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease 15.

In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) 11, 12, 13, 14, 15, 16, 8, 9.

Its effect is more potent on

PDE5 than on other known phosphodiesterases 11, 12, 13, 14, 15, 16, 8, 9.

In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina 11, 12, 13, 14, 15, 16, 8, 9.

There is an 80-times selectivity over PDE1, and over 700-times over PDE and 11 11, 12, 13, 14, 15, 16, 8, 9.

And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility 11, 12, 13, 14, 15, 16, 8, 9.

In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo 11, 12, 13, 14, 15, 16, 8, 9.

Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose 11, 12, 13, 14, 15, 16, 8, 9.

The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration 11, 12, 13, 14, 15, 16, 8, 9.

The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours 11, 12, 13, 14, 15, 16, 8, 9.

Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects 11, 12, 13, 14, 15, 16, 8, 9.

After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively 11, 12, 13, 14, 15, 16, 8, 9.

After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg) 11, 12, 13, 14, 15, 16, 8, 9.

At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen 11, 12, 13, 14, 15, 16, 8, 9.

Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG 11, 12, 13, 14, 15, 16, 8, 9.

After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either 11, 12, 13, 14, 15, 16, 8, 9.

In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline 11, 12, 13, 14, 15, 16, 8, 9.

Mean pulmonary systolic blood pressure decreased by 9% 11, 12, 13, 14, 15, 16, 8, 9.

Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries 11, 12, 13, 14, 15, 16, 8, 9.

Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose 11, 12, 13, 14, 15, 16, 8, 9.

The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina 11, 12, 13, 14, 15, 16, 8, 9.

Sildenafil has no effect on visual acuity or contrast sensitivity.

In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) 11, 12, 13, 14, 15, 16, 8, 9.

cGMP-specific 3',5'-cyclic phosphodiesterase Inhibitor.

Sildenafil is known to be quickly absorbed, with maximum plasma concentrations being observed within 30-120 minutes (with a median of 60 minutes) of oral administration in a fasting patient 11, 12, 13, 14, 15, 16, 8, 9.

Moreover, the mean absolute bioavailability observed for sildenafil is about 41% (from a range of 25-63%) 11, 12, 13, 14, 15, 16, 8, 9.

In particular, after oral three times a day dosing of sildenafil, the AUC and Cmax increase in proportion with dose over the recommended dosage range of 25-100 mg 11, 12, 13, 14, 15, 16, 8, 9.

When used in pulmonary arterial hypertension patients, however, the oral bioavailability of sildenafil after a dosing regimen of 80 mg three times a day, was on average 43% greater than compared to the lower doses 11, 12, 13, 14, 15, 16, 8, 9.

Finally, if sildenafil is administered Oral with food, the rate of absorption is observed to be decreased with a mean delay in Tmax of about 60 minutes and a mean decrease in Cmax of approximately 29% 11, 12, 13, 14, 15, 16, 8, 9.

Regardless, the extent of absorption is not observed to be significantly affected as the recorded AUC decreased by only about 11 % 11, 12, 13, 14, 15, 16, 8, 9.

The mean steady-state volume of distribution documented for sildenafil is approximately 105 L.

• a value which suggests the medication undergoes distribution into the tissues 11, 12, 13, 14, 15, 16, 8, 9.

The metabolism of sildenafil is facilitated primarily by the CYP3A4 hepatic microsomal isoenzymes and to a minor extent, via the CYP2C9 hepatic isoenzymes 6, 11, 12, 13, 14, 15, 16, 8, 9.

The predominant circulating metabolite results from the N-demethylation of sildenafil 6, 11, 12, 13, 14, 15, 16, 8, 9.

This particular resultant metabolite possesses a phosphodiesterase selectivity that is similar to the parent sildenafil molecule and a corresponding in vitro potency for PDE5 that is approximately 50% that of the parent drug 6, 11, 12, 13, 14, 15, 16, 8, 9.

Moreover, plasma concentrations of the metabolite are about 40% of those recorded for sildenafil, a percentage that accounts for about 20% of sildenafil's pharmacologic effects 6, 11, 12, 13, 14, 15, 16, 8, 9.

This primary

N-desmethyl metabolite of sildenafil also undergoes further metabolism, with a terminal half-life of about 4 hours 6, 11, 12, 13, 14, 15, 16, 8, 9.

In patients with pulmonary arterial hypertension, plasma concentrations of the primary N-desmethyl metabolite are about 72% those of the original parent sildenafil molecule after a regimen of 20 mg three times a day.

• which is consequently responsible for about a 36% contribution to sildenafil's overall pharmacological effects 6, 11, 12, 13, 14, 15, 16, 8, 9.

Hover over products below to view reaction partners Sildenafil N-Desmethyl sildenafil (UK-103,320) N-Desmethyl sildenafil.

After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose) 11, 12, 13, 14, 15, 16, 8, 9.

The terminal phase half-life observed for sildenafil is approximately 3-5 hours 11, 12, 13, 14, 15, 16, 8, 9.

The total body clearance documented for sildenafil is 41 L/h 11, 12, 13, 14, 15, 16, 8, 9.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

In single-dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased 11, 12, 13, 14, 15, 16, 8, 9.

Doses of 200 mg did not result in increased efficacy but the incidence of adverse reaction (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased 11, 12, 13, 14, 15, 16, 8, 9.

Due to the lack of data on the effect of sildenafil indicated for the treatment of pulmonary arterial hypertension (PAH) in pregnant women, sildenafil is not recommended for women of childbearing potential unless also using appropriate contraceptive measures 11, 14, 15, 9.

The safety and efficacy of sildenafil indicated for treating PAH in a woman during labor and delivery have not been studied 11, 14, 15, 9.

Caution should ultimately be exercised when sildenafil is administered to nursing women as it is not known if sildenafil or its metabolites are excreted in human breast milk 11, 14, 15, 9.

The safety and efficacy of sildenafil for the treatment of PAH in children below 1 year of age has not been established as no data is available 15.

Clinical experience with the elderly population in the use of sildenafil for the treatment of PAH has been varied.

Some reports suggest that there are no identified differences in responses between elderly and younger patients 11 while others have documented that clinical efficacy as measured by 6-minute walk distance could be less in elderly patients 9.

In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy 11.

Conversely, when sildenafil was used to treat erectile dysfunction in healthy elderly volunteers (65 years or over), a reduced clearance of sildenafil was observed 12, 8.

This reduction resulted in about 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years) 12, 8.

Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately 40% 12, 8.

Sildenafil was not carcinogenic when administered to rats for 24 months at a dose resulting in total systemic drug exposure (AUCs) for unbound sildenafil and its major metabolite of 29.

• and 42.

• times, for male and female rats, respectively, the exposures observed in human males given the Maximum Recommended Human Dose (MRHD) of 100 mg 11, 12, 13, 14, 15, 16, 8, 9.

Sildenafil was not carcinogenic when administered to mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 10 mg/kg/day, approximately 0.6 times the MRHD on a mg/m2 basis 11, 12, 13, 14, 15, 16, 8, 9.

Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and in vitro human lymphocytes and in vivo mouse micronucleus assays to detect clastogenicity 11, 12, 13, 14, 15, 16, 8, 9.

There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 36 days to females and 102 days to males, a dose producing an AUC value of more than 25 times the human male AUC 11, 12, 13, 14, 15, 16, 8, 9.

Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form.

Sildenafil tablets was shown to potentiate the hypotensive effect of nitrates Known hypersensitivity to sildenafil or any component of tablet Administration with guanylate cyclase (GC) stimulators, such as riociguat 4.1 Nitrates Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil tablets was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated.

After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered.

Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point. 4.2 Hypersensitivity Reactions Sildenafil tablets are contraindicated in patients with a known hypersensitivity to sildenafil, as contained in sildenafil tablets and REVATIO, or any component of the tablet.

Hypersensitivity reactions have been reported, including rash and urticaria. 4.3 Concomitant Guanylate Cyclase (GC) Stimulators Do not use sildenafil tablets in patients who are using a GC stimulator, such as riociguat.

PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of GC stimulators.

For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity.

However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg Maximum recommended dosing frequency is once per day 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity.

However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity.

The maximum recommended dosing frequency is once per day. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.3 Dosage Adjustments in Specific Situations Sildenafil tablets was shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors such as organic nitrates or organic nitrites in any form is therefore contraindicated.

When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold.

CYP3A4 Inhibitors Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin.

Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold. 2.5 Dosage Adjustments in Special Populations Consider a starting dose of 25 mg in patients > 65 years, patients with hepatic impairment (e.g., cirrhosis), and patients with severe renal impairment (creatinine clearance <30 mL/minute) because administration of sildenafil tablets in these patients resulted in higher plasma levels of sildenafil.

Sildenafil tablets

USP are supplied as pale blue to blue, caplet shaped film-coated tablets containing sildenafil citrate equivalent to the nominally indicated amount of sildenafil as follows: For 25 mg.

• Pale blue to blue, round film-coated tablets, debossed with “25” on one side and “SL” on other side.

NDC 72789-404-30 Bottles of 30 Tablets NDC 72789-404-90 Bottles of 90 Tablets Recommended Storage: Store at 25°C (77°F); excursions permitted within 15-30°C (59-86°F) .

Sildenafil is not indicated for use in females.

There are no data with the use of sildenafil in pregnant women to inform any drug-associated risks for adverse developmental outcomes.

Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m 2 basis.

No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis.

These doses represent, respectively, about and 32 times the MRHD on a mg/m 2 basis in a 50 kg subject.

In the rat pre.

• and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m 2 basis in a 50 kg subject.

Sildenafil is not indicated for use in pediatric patients.

Safety and effectiveness have not been established in pediatric patients.

Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) .

Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively.

Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older.

No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger (< 65 years of age) subjects.

However, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure.